Search

Displaying results 5641 - 5650 of 10000 in total
  1. Drug

    OBE101

    go.drugbank.com/drugs/DB05080
    Experimental

    Obecure is repurposing betahistine, which is an H1 receptor agonist and partial H3 receptor antagonist for the treatment of obese individuals and for other weight management indications. … OBE101 is a new weight loss drug developed by Obecure Ltd. It is a new formulation that is based on the vertigo medication, Betahistine.

  2. Drug

    Onercept

    go.drugbank.com/drugs/DB06495
    Investigational

    Synonyms: R-HTBP-1
  3. Drug

    Maytansine

    go.drugbank.com/drugs/DB19582
    Investigational

    Maytansine is a small molecule drug. Maytansine is under investigation in clinical trial NCT04189211 (A Clinical Trial of BAT8001 on Safety, Tolerability and Pharmacokinetics for Patients).

  4. Drug

    RD06-04

    go.drugbank.com/drugs/DB24647
    Investigational

    RD06-04 is under investigation in clinical trial NCT06986018 (Clinical Study on the Targeted CD19 Universal CAR-T Cell Injection (RD06-04) for the Treatment of IIM and AAV). … RD06-04 is a biologic drug.

  5. Drug

    Upinitatug rilsodotin

    go.drugbank.com/drugs/DB19104
    Investigational

    Upinitatug rilsodotin is under investigation in clinical trial NCT05329545 (Upifitamab Rilsodotin Maintenance in Platinum-sensitive Recurrent Ovarian Cancer (UP-NEXT)).

  6. Drug

    Filanesib

    go.drugbank.com/drugs/DB06040
    Investigational

    Filanesib is a potent Kinesin Spindle Protein (KSP) inhibitor that caused marked tumor regression in preclinical models of human solid tumors and human leukemias, often leading to durable responses.

  7. Drug

    Tanaproget

    go.drugbank.com/drugs/DB04787
    Experimental

    Because of this tanaproget may prove to produce fewer side effects in comparison. It is currently in the process of being developed for clinical use as a contraceptive by Ligand Pharmaceuticals. … An analog of tanaproget, 4-fluoropropyltanaproget (18F), has been developed as a radiotracer for imaging of the PR in positron emission tomography.

  8. Drug

    Forodesine

    go.drugbank.com/drugs/DB06185
    Investigational

    Additional preliminary findings support its use for the management of some B-cell malignancies. … Forodesine is a highly potent, orally active, rationally designed PNP inhibitor that has shown activity in preclinical studies with malignant cells and clinical utility against T-cell acute lymphoblastic

  9. Drug

    Bertilimumab

    go.drugbank.com/drugs/DB05429
    Investigational

    It is developed by MedImmune for the treatment of Allergic Rhinitis. … Bertilimumab is a fully human anti-eotaxin monoclonal antibody with potential in the treatment of allergic disorders, has moved into pre-clinical development.

  10. Drug

    ADL 10-0101

    go.drugbank.com/drugs/DB05443
    Experimental

    Because ADL 10-0101 does not cross the blood-brain barrier and enter the brain when administered at therapeutic doses, it is expected to avoid central nervous system side effects. … Preclinical trials of ADL 10-0101 have suggested that the compound may be effective for the treatment of inflammatory pain, itch and visceral pain.